 "Strides Pharma Science, Chief Executive Officer R ANANTHANARAYANAN")
Riding on strong sales, Strides Pharma Science has reported a consolidated net profit of Rs 43.74 crore in the fourth quarter of FY20. The company had posted a consolidated net loss of Rs 206.57 crore in the corresponding quarter a year ago.
Revenue from operations in the fourth quarter stood at Rs 908.49 crore which was at Rs 618.64 crore in the year-ago period.
“Amidst a tough operating environment, we are pleased to have delivered a healthy performance across all businesses in FY21. Our regulated markets franchise which now contributes 80 per cent of revenues has seen significant ramp up
